Andreas Hierlemann

Aug 21, 2024 | nature.com | Matteo Cartiglia |Shyam Narayanan |Hasan Uluşan |Andreas Hierlemann |Fernando Cardes

AbstractBio-signal sensing is pivotal in medical bioelectronics. Traditional methods focus on high sampling rates, leading to large amounts of irrelevant data and high energy consumption. We introduce a self-clocked microelectrode array (MEA) that digitizes bio-signals at the pixel level by encoding changes as asynchronous digital address-events only when they exceed a threshold, significantly reducing off-chip data transmission.

Feb 20, 2024 | nature.com | Alessio Paolo Buccino |Julian Bartram |Sreedhar Saseendran Kumar |Michele M. Nava |Andreas Hierlemann

AbstractA growing consensus that the brain is a mechanosensitive organ is driving the need for tools that mechanically stimulate and simultaneously record the electrophysiological response of neurons within neuronal networks.

Feb 14, 2024 | nature.com | Marian Hruska-Plochan |Vera I. Wiersma |Katharina M. Betz |Elena Tantardini |Florent Laferrière |Igor Delvendahl | +11 more

AbstractHuman cellular models of neurodegeneration require reproducibility and longevity, which is necessary for simulating age-dependent diseases. Such systems are particularly needed for TDP-43 proteinopathies1, which involve human-specific mechanisms2,3,4,5 that cannot be directly studied in animal models.

Jan 3, 2024 | nature.com | Marek Basler |Petr Broz |Knut Drescher |Alexander Harms |Andreas Hierlemann |Sebastian Hiller | +11 more

In vitro models mimicking in-patient conditions have the potential to yield exciting opportunities for antibiotic research and revitalize future antibiotic discovery and development. Antibiotics have revolutionized modern medicine. However, their usefulness in treating bacterial infections and as prophylactics accompanying chemotherapy or surgery is under threat by the rise of antibiotic-resistant bacteria.

Dec 8, 2023 | nature.com | Mahshid Gazorpak |Karina M. Hugentobler |Pierre-Luc Germain |Miriam Kretschmer |Iryna Ivanova |Kei Mathis | +10 more

AbstractCounteracting the overactivation of glucocorticoid receptors (GR) is an important therapeutic goal in stress-related psychiatry and beyond. The only clinically approved GR antagonist lacks selectivity and induces unwanted side effects. To complement existing tools of small-molecule-based inhibitors, we present a highly potent, catalytically-driven GR degrader, KH-103, based on proteolysis-targeting chimera technology.